Neuropace (NPCE) had the highest return between January 1, 2023 and January 31, 2023 by a small-cap US stock or small-cap US stock, returning 239.1%.
| ASSET | DATE | % RETURN |
|---|---|---|
Neuropace (NPCE) | 1/1/2023 - 1/31/2023 | 239.13% |
Clene (CLNNW) | 1/1/2023 - 1/31/2023 | 185.25% |
Yirendai (YRD) | 1/1/2023 - 1/31/2023 | 141.9% |
Bit Digital (BTBT) | 1/1/2023 - 1/31/2023 | 132.26% |
HIVE Blockchain Technologies (HIVE) | 1/1/2023 - 1/31/2023 | 132.21% |
Bitfarms (BITF) | 1/1/2023 - 1/31/2023 | 126.15% |
Immunome (IMNM) | 1/1/2023 - 1/31/2023 | 120.42% |
GCM Grosvenor (GCMGW) | 1/1/2023 - 1/31/2023 | 118.6% |
Praxis Precision Medicines (PRAX) | 1/1/2023 - 1/31/2023 | 118.42% |
GD Culture (GDC) | 1/1/2023 - 1/31/2023 | 111.67% |
So-Young International (SY) | 1/1/2023 - 1/31/2023 | 101.43% |
Olema Pharmaceuticals (OLMA) | 1/1/2023 - 1/31/2023 | 94.76% |
Quantum-Si (QSIAW) | 1/1/2023 - 1/31/2023 | 93.75% |
Clear Channel Outdoor (CCO) | 1/1/2023 - 1/31/2023 | 81.9% |
Lendingtree (TREE) | 1/1/2023 - 1/31/2023 | 81.59% |
Cooper Stnd (CPS) | 1/1/2023 - 1/31/2023 | 79.68% |
D-MARKET Electronic Services & Trading ADR (HEPS) | 1/1/2023 - 1/31/2023 | 74.93% |
Lexinfintech (LX) | 1/1/2023 - 1/31/2023 | 71.13% |
Savara (SVRA) | 1/1/2023 - 1/31/2023 | 71.05% |
Standard Biotools (LAB) | 1/1/2023 - 1/31/2023 | 70.94% |
Fulcrum Therapeutics (FULC) | 1/1/2023 - 1/31/2023 | 70.64% |
American Coastal Insurance (ACIC) | 1/1/2023 - 1/31/2023 | 70.63% |
CureVac (CVAC) | 1/1/2023 - 1/31/2023 | 70.21% |
Aehr Test Systems (AEHR) | 1/1/2023 - 1/31/2023 | 70.19% |
Janux Therapeutics (JANX) | 1/1/2023 - 1/31/2023 | 67.12% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
